Literature DB >> 22902639

UHRF2, another E3 ubiquitin ligase for p53.

Lu Bai1, Xiaohui Wang, Fangmin Jin, Yan Yang, Guanhua Qian, Changzhu Duan.   

Abstract

UHRF2, ubiquitin-like with PHD and ring finger domains 2, is a nuclear E3 ubiquitin ligase, which is involved in cell cycle and epigenetic regulation. UHRF2 interacts with multiple cell cycle proteins, including cyclins (A2, B1, D1, and E1), CDK2, and pRb; moreover, UHRF2 could ubiquitinate cyclin D1 and cyclin E1. Also, UHRF2 has been shown to be implicated in epigenetic regulation by associating with DNMTs, G9a, HDAC1, H3K9me2/3 and hemi-methylated DNA. We found that UHRF2 associates with tumor suppressor protein p53, and p53 is ubiquitinated by UHRF2 in vivo and in vitro. Given that both UHRF2 and p53 are involved in cell cycle regulation, this study may suggest a novel signaling pathway on cell proliferation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902639     DOI: 10.1016/j.bbrc.2012.08.009

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  UHRF2, a ubiquitin E3 ligase, acts as a small ubiquitin-like modifier E3 ligase for zinc finger protein 131.

Authors:  Yohan Oh; Kwang Chul Chung
Journal:  J Biol Chem       Date:  2013-02-12       Impact factor: 5.157

2.  Loss of UHRF2 Is Associated With Non-small Cell Lung Carcinoma Progression.

Authors:  Chun Jin; Dian Xiong; Hao-Ran Li; Jia-Hao Jiang; Jian-Chao Qi; Jian-Yong Ding
Journal:  J Cancer       Date:  2018-07-30       Impact factor: 4.207

3.  MiRNA expression profile for the human gastric antrum region using ultra-deep sequencing.

Authors:  Fabiano Cordeiro Moreira; Monica Assumpção; Igor G Hamoy; Sylvain Darnet; Rommel Burbano; André Khayat; André Nicolau Gonçalves; Dayse O Alencar; Aline Cruz; Leandro Magalhães; Wilson Araújo; Artur Silva; Sidney Santos; Samia Demachki; Paulo Assumpção; Andrea Ribeiro-dos-Santos
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.